Singapore markets open in 7 hours

Provectus Biopharmaceuticals, Inc. (PVCT)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.1900-0.0049 (-2.49%)
As of 12:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.1948
Open0.1948
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.1809 - 0.1948
52-week range0.0560 - 0.2250
Volume50,634
Avg. volume336,940
Market cap79.688M
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings date10 May 2024 - 14 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

    Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancer

  • GlobeNewswire

    Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

    Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced additions to its executive leadership team, reflecting Provectus's dedication to enhancing shareholder value. The Company’s Board of Directors (the “Board”) has appointed Ed Pershing as Chief Executive Officer (“CEO”) and Dominic Rodrigues as President. New Executive Appoin

  • GlobeNewswire

    Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting

    PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by Moffitt Cancer Center (“Moffitt”) on PV-10 (rose bengal sodium) for the treatments of human papillomavirus (“HPV”)-positive and HPV-negative head and neck squamous cell carcinoma (“HNSCC”) were presented at the annual meeting of th